Last reviewed · How we verify
A Phase I, Randomized, Observer-blind, Placebo Controlled Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Venezuelan Equine Encephalitis DNA Vaccine Candidate Administered Intramuscularly or Intradermally by Electroporation to Healthy Adults
The Phase I study will assess the basic safety, tolerability, and immunogenicity of a DNA-based Venezuelan equine encephalitis virus (VEEV)vaccine candidate delivered by electroporation . The study will enroll 40 healthy adult volunteers ages 18-49 and will comprise evaluation of intradermal or intramuscular administration by electroporation. Administration of the vaccine candidate will be at two DNA dose levels (0.5 mg/ml and 2.0 mg/ml) for each route of administration. Electroporation will be administered using the TriGrid Delivery System devices for intramuscular and intradermal delivery. An additional group of subjects will serve as a placebo control, receiving injections of saline with electroporation. The overall goal of this study will be to determine if further human clinical studies of the vaccine candidate are warranted and, if so, to aid in the selection of dose and route of administration for future studies.
Details
| Lead sponsor | Ichor Medical Systems Incorporated |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 42 |
| Start date | 2013-12 |
| Completion | 2015-05 |
Conditions
- Venezuelan Equine Encephalitis Virus Infection
Interventions
- Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
- 0.9% saline placebo
Primary outcomes
- The nature, frequency, and severity of local and systemic adverse events or serious adverse events associated with electroporation-based administration of the VEEV DNA vaccine candidate — 12 months
Countries
United States